Company Description

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe.

It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.

In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories.

The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product.

Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.

Mainz Biomed N.V.

Country	Germany
Founded	2008
IPO Date	Nov 5, 2021
Industry	Medical - Diagnostics & Research
Sector	Healthcare
Employees	26
CEO	Guido Baechler

Contact Details

Address: Robert Koch Strasse 50 Mainz, 55129 Germany
Phone	49 6131 554 2860
Website	mainzbiomed.com

Stock Details

Ticker Symbol	QUCY
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1874252
ISIN Number	NL0015000LC2
SIC Code	2834

Key Executives

Name	Position
Guido Baechler	Chief Executive Officer
William Caragol	Chief Financial Officer
Christopher Von Toerne	Chief Operating Officer

Latest SEC Filings

Date	Type	Title
Mar 12, 2026	PRE 14A	Other preliminary proxy statements
Mar 11, 2026	8-K	Current Report
Feb 19, 2026	S-8	Securities to be offered to employees in employee benefit plans
Feb 17, 2026	SCHEDULE 13G/A	Filing
Feb 17, 2026	8-K	Current Report
Feb 10, 2026	8-K	Current Report
Jan 20, 2026	SCHEDULE 13G/A	Filing
Jan 16, 2026	SCHEDULE 13G	Filing
Dec 29, 2025	EFFECT	Notice of Effectiveness
Dec 29, 2025	424B5	Filing

View All SEC Filings